Natividad Romero
Natividad Romero has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Angela Hernandez-Martin
Department of Dermatology Hospital Infantil Universitario Niño Jesús Madrid Spain
1 shared publication - Beatriz Aranegui
Servicio de Dermatología, Hospital Universitario Infanta Cristina , Parla, Madrid, España
1 shared publication - Esther Domínguez
The Dystrophic Epidermolysis Bullosa Research Association (DEBRA), Spain, Spain
1 shared publication - Eva Monrós
DEBRA member, Madrid, Spain
1 shared publication - Evanina Morcillo-Makow
The Dystrophic Epidermolysis Bullosa Research Association (DEBRA), Spain, Spain
1 shared publication - Ignacio Garcia Doval
Dermatology Department, Complexo Hospitalario Universitario de Vigo , Vigo
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 61
Prioritization of therapy uncertainties in Dystrophic Epidermolysis Bullosa: where should research direct to? an example of priority setting partnership in very rare disorders
Dystrophic Epidermolysis Bullosa (DEB) is a rare genodermatosis (7 cases per million) that causes blisters and erosions with minor trauma in skin and mucosa, and other systemic complications. A recently updated systematic review showed that the research evidence about DEB therapies is poor. As new trials in DEB are difficult and expensive, it is important to prioritizise research that patients and clinicians consider more relevant.
- 1 January 2013
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 61
Open AccessPrioritization of therapy uncertainties in Dystrophic Epidermolysis Bullosa: where should research direct to? an example of priority setting partnership in very rare disorders
Dystrophic Epidermolysis Bullosa (DEB) is a rare genodermatosis (7 cases per million) that causes blisters and erosions with minor trauma in skin and mucosa, and other systemic complications. A recently updated systematic review showed that the research evidence about DEB therapies is poor. As new trials in DEB are difficult and expensive, it is important to prioritizise research that patients and clinicians consider more relevant.